IBA Health has had a mixed year. It has shown a profit this year and thought it had made a significant deal in the UK market for distributing its products. This has become un-stuck with the iSoft/Torex merger plan but IBA has solidified its position in Asia and in its home markets. The company needs to rapidly attract the right partners globally and create a much stronger ecosystem. It claims to be more focused on the Asian markets but needs to be a player globally. The company also needs to continue its focus on earnings this year and continue with its acquisition program.

Note: TekPlus Points state the current opinion of the vendor as viewed by TekPlus. TekPlus experts take a number of parameters into account when analysing a vendor and its position in the competitive landscape going forward. The scale of the points are as follows; +3 : Extremely Solid Position, +2 : Solid Position, +1 : Promising Position, 0 : Weak Position and -1 : Very Weak Position.

SWOT
Strengths
Weaknesses
Opportunities
Threats

Primary Details
Headquarters
Website
Company  
Regional Operations:
Australia
New Zealand
Singapore and
United Kingdom
Management

Finance
FY 2003

Employees

Products

Competitive Factors
Competitors

Directions
Opportunities in its Home land 
  

List of Tables
Table 1: Board of Directors
Table 2: IBA Health Limited: Key 2003 Figures
Table 3: IBA Health Limited: Operational Results
Table 4: IBA Product Line
Table 5: Competitors of IBA Health
 

List of Figures
IBA Health: Product sale (Approximate)